MedTrace Logo

Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics

NCT03006991 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-12-30

No results posted yet for this study

Summary

This study will integrate Pharmacogenomics and Pharmacometrics, to explore an effective concentration of MTXPGn for JIA pediatric patients, and set up a Population Pharmacokinetics model to provide reference for individual administration on JIA pediatric patients.

Conditions

  • Juvenile Idiopathic Arthritis

Interventions

OTHER

therapeutic drug monitoring

dose of methotrexate can be adjusted by therapeutic drug monitoring.

Sponsors & Collaborators

  • Guangzhou Women and Children's Medical Center

    lead OTHER

Principal Investigators

  • Xiaolan Mo, master · Guangzhou Women and Children's Medical Center

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2020-12-31
Completion
2023-12-31

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03006991 on ClinicalTrials.gov